Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
The Metabolic Revolution in Dermatology: Screening, Treatment, and the Role of GLP-1s
Description
The talk argues that metabolic disease is a major driver of skin inflammation and that dermatologists are often the first, and sometimes only, clinicians positioned to identify it. It reviews common cutaneous clues of insulin resistance and obesity such as acanthosis nigricans, skin tags, dorsal cervical fat pad, hirsutism, hormonal acne, psoriasis, hidradenitis suppurativa, and some atopic conditions. The speaker emphasizes that normal A1C can miss significant hyperinsulinemia, so dermatologists should consider fasting glucose, fasting insulin, HOMA-IR, lipid panel, liver enzymes, A1C, and sometimes testosterone, DHEAS, C-peptide, IGF, and thyroid studies. The presentation highlights GLP-1 therapies, especially semaglutide and tirzepatide, as important tools for weight loss and metabolic improvement, with potential benefits for hospitalization rates, cardiometabolic risk, and some skin diseases. Counseling points include slow dose escalation, monitoring for GI side effects, gallstones, rare pancreatitis, thyroid cancer contraindications, maintaining protein intake, resistance training, hydration, and weekly weigh-ins. Overall, the message is that dermatologists should proactively screen, educate, and help manage metabolic disease rather than waiting for delayed specialist care.
View moreConclusions
- Metabolic disease is presented as a major hidden driver of inflammatory skin disease, so dermatologists should look beyond the skin findings alone.
- Skin changes such as acanthosis nigricans, skin tags, dorsal cervical fat pads, and hirsutism can serve as early visible clues to insulin resistance and broader metabolic dysfunction.
- Normal A1c or glucose values do not rule out clinically important insulin resistance, so fasting insulin and HOMA-IR can uncover disease that standard screening misses.
- Obesity and psoriasis appear to reinforce each other, and treating only the skin may leave the underlying metabolic inflammation untreated.
- Obesity also worsens outcomes in atopic disease and hidradenitis suppurativa, making weight and metabolic management part of dermatologic care.
- Hormonal acne and PCOS should prompt evaluation for insulin resistance because hyperinsulinemia can drive androgen excess and acne severity.
- GLP-1–based therapies, especially semaglutide and tirzepatide, are portrayed as effective tools for improving weight, glycemic control, and related inflammatory disease burden.
- Compared with semaglutide, tirzepatide may produce greater average weight loss with better lean mass preservation and may be preferable for some patients.
- Dermatologists are encouraged to screen for metabolic disease with labs such as fasting glucose, fasting insulin, lipid panel, AST/ALT, A1c, and selected endocrine markers when indicated.
- Routine lab monitoring is limited for GLP-1 therapy, but patients need close clinical follow-up, weekly weight tracking, blood pressure monitoring when relevant, and counseling on contraception, protein intake, resistance training, hydration, and side effects.
- The overall conclusion is that dermatologists should act early as accessible gatekeepers for systemic metabolic disease, particularly where specialist access is limited.
- Nicklas JM et al. American Journal of Preventive Medicine
- Wing RR, Phelan S. American Journal of Clinical Nutrition
- Kaiser Family Foundation
- McAdam-Marx et al.
- Patorno et al.
- Cruz and Hud, 1992
- Sinha and Schwartz, 2007